LZAGY
Lonza Group AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
73.87
▲ 0.89 (1.22%)
MARKET · —
Price
Open
73.34
Prev close
72.98
Day high
74.00
Day low
73.26
Volume
4.86K
Market cap
$52.56B
P/E (TTM)
38.08
52W range
58.53 – 74.00
Trailing performance
Returnvs SPY
1W
+6.90%
+8.3%
1M
+11.49%
+7.8%
3M
+16.09%
+13.0%
6M
+6.66%
-4.4%
YTD
+9.94%
-2.3%
1Y
+3.65%
-16.4%
3Y
+36.85%
-37.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$52.56B
Enterprise value$55.26B
Revenue (TTM)$6.87B
Gross profit$2.55B
EBITDA$2.39B
Net income$1.08B
EPS (TTM)$1.94
Free cash flow$-1.57B
Total cash$487.00M
Total debt$4.17B
Book value / share$14.55
Shares outstanding698.44M
Float697.41M
Short % of float—
Dividend yield0.86%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E38.08
Forward P/E26.05
PEG ratio1.28
Price / sales—
Price / book5.08
EV / revenue8.04
EV / EBITDA23.12
Gross margin37.14%
Operating margin23.41%
Profit margin-1.60%
Return on equity12.90%
Return on assets5.44%
Debt / equity51.12
Current ratio1.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $6.53B | $6.57B | $6.72B | $6.22B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $949.00M | $636.00M | $654.00M | $1.22B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $949.00M | $636.00M | $654.00M | $1.22B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 1.72 | 2 | $7.13B | +9.2% |
| Next year | 2.27 | 3 | $7.96B | +11.6% |
Analyst targets & ownership
Mean target$83.14
High target$88.76
Low target$80.04
Implied upside12.55%
Analyst count3
ConsensusNONE
Strong buy / Buy1 / 1
Hold1
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.04%
Institutions holding18
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Moving averages & technicals
SMA 10
71.02
+4.01% from price
SMA 20
70.29
+5.10% from price
SMA 50
68.55
+7.76% from price
SMA 100
65.87
+12.14% from price
SMA 200
66.34
+11.34% from price
EMA 12
71.16
+3.80% from price
EMA 26
70.15
+5.30% from price
EMA 50
68.76
+7.43% from price
RSI (14)
65.8
Neutral
MACD (12,26,9)
1.02
Hist 0.29
ATR (14)
1.24
1.68% of price
Realised vol 30D
27.5%
Annualised
Bollinger upper
73.25
20, 2σ
Bollinger lower
67.33
20, 2σ
50 / 200 cross
Golden
68.55 vs 66.34
Trend bias
Above 200
+11.34%
Risk profile
Beta vs SPY
0.72
Less volatile than market
Correlation to SPY
0.37
Loosely linked
Realised vol 30D
27.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-20.2%
Peak to trough
Max drawdown 5Y
-59.6%
Peak to trough
ATR 14
1.24
1.68% of price
Beta (reported)
0.84
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
Zacks · 44d ago
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
PR Newswire · 45d ago
[Latest] Global Bioprocess Digital Twin Market Size/Share Worth USD 6.47 Billion by 2035 at a 19.6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
GlobeNewswire · 58d ago
[Latest] Global Stem Cell Culture Media Market Size/Share Worth USD 2714 Million by 2035 at a 13.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
GlobeNewswire · 59d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.